Researchers have revealed a direct relationship between two specific antibodies and the severity of Alzheimer’s disease symptoms, raising hopes that a diagnostic blood test for the devastating disorder is within reach.

A drug used in a type of hereditary metabolic disorder improved the memory of laboratory animals with Alzheimer’s disease.

By the time they have been diagnosed with Alzheimer’s disease, many patients’ decision-making ability is so impaired that they cannot give informed consent to participate in research studies.

New research into the effects of antipsychotic drugs commonly prescribed to Alzheimer’s patients concludes that the medication nearly doubles risk of death over three years.

Just three months after Microsoft Corp. released its data management and business intelligence platform, Microsoft SQL Server 2008, several large customers are using the database software to scale new heights in data warehousing and transaction processing.

A study in the Sept. 21 on-line edition of Nature Medicine describes the function and interaction of a critical molecule involved in cell death in Alzheimer’s disease patients.

One of the hallmarks of Alzheimer’s disease is the formation of plaques made of protein aggregates in the brain tissue. There is still considerable debate among scientists as to whether these plaques are the cause of the neuronal death that occurs in Alzheimer’s or just a by-product of the disease, however.

Researchers at the National Institute of Standards and Technology (NIST) and three collaborating institutions are using a new laboratory model of the membrane surrounding neurons in the brain to study how a protein long suspected of a role in early-stage Alzheimer’s disease actually impairs a neuron’s structure and function. The team’s findings are reported in a new paper in the Biophysical Journal.

Researchers at Robarts Research Institute at The University of Western Ontario have found clear evidence that increases in the size of the brain ventricles are directly associated with cognitive impairment and Alzheimer’s disease.

The humble tomato could be a suitable carrier for an oral vaccine against Alzheimer’s disease, according to HyunSoon Kim from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) in Korea and colleagues from Digital Biotech Inc. and the Department of Biological Science at Wonkwang University.

An Australian research project has found a way to bring forward the detection of early stage Alzheimer’s disease by up to 18 months.